UCSF Helen Diller Family Comprehensive Cancer Center
Protocol Summary

[ Back to Protocol Listing ]

[ Print this page ]

Protocol No.RTOG-1115Principal InvestigatorRoach III, Mack
PhaseIII (Cancer Control)
Age GroupAdultScopeNational
TitlePhase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GNRH Agonist vs Dose Escalated Radiation Therapy and Enhanced ADT with a GNRH Agonist and TAK-700 for Men with High Risk Prostate Cancer
ObjectiveTo evaluate the difference in overall survival in men with clinically localized prostate cancer with unfavorable prognostic features between a) standard treatment (ADT + radiotherapy) and b) standard treatment with the addition of 24 months of TAK-700.
Key Eligibility* Histologically confirmed diagnosis of adenocarcinoma of the prostate * Clinically negative lymph nodes as established by imaging
Applicable Disease SitesProstate
Drugs InvolvedOrteronel
StatusOpen
Participating InstitutionsMt. Zion : Paula Dutton
Eligibility DocumentRTOG-1115_CTGovEligibility_NCT01546987.doc
ContactPaula Dutton Phone:415-885-7871
Pager:
Email:walshp@medicine.ucsf.edu